# Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease

Source: https://onco.cc/key-papers/paper-heo-cancerdetect-validation-plos-one-2025/  
OnCo record `paper-heo-cancerdetect-validation-plos-one-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The laboratory validation of IMBdx's personalised blood test for leftover cancer, which reached one part in 100,000 on test mixtures.

## Summary

CancerDetect (formerly reported as AlphaLiquid Detect) combines personalised (bespoke) mutations with tumour-agnostic actionable hotspot mutations in a hybridisation-capture assay. Its analytical validation reported a limit of detection down to 0.001 per cent (10^-5) with 99.9 per cent specificity.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: PLoS One
- Year: 2025
- DOI: 10.1371/journal.pone.0334282
- Authors: Heo S, Ham SK, Lee H, et al.
- Findings: Limit of detection 0.001% (10^-5) with 99.9% specificity.
- What it means: A Korean residual disease test reports a limit at ten parts per million, on germline-variant mixtures rather than tumour plasma.
- Caveats: The full text measured the bespoke limit on a 385-SNP cell-line mixture; hotspot regions had a limit of 0.1 per cent.

## Sources

- Heo et al., PLoS One 2025: https://doi.org/10.1371/journal.pone.0334282
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41212866/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [CancerDetect](https://onco.cc/drugs/cancerdetect-imbdx/)
- companies: [IMBdx](https://onco.cc/companies/imbdx/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)

---
JSON: https://onco.cc/api/v1/entities/paper-heo-cancerdetect-validation-plos-one-2025.json